Invea Therapeutics
PrivateLast Round
IPO
Mar 6, 2026
Est. Valuation
$127.5M
Total Funding Raised
$14.76M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Invea Therapeutics operates in Healthcare & Life Sciences and is based in Guilford, Connecticut. Its latest recorded funding round was a Convertible Debt round in March 2025.
Invea Therapeutics is a biotechnology company developing oral small molecule therapeutics for immune-mediated inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Invea Therapeutics Comparables
Compare Invea Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Evommune | 84% | |
| Septerna | 79% | |
| Incyte Corporation | 75% |
For institutional investors. Book with your work email.
Invea Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 6, 2026 | ||||
| Convertible Debt | Mar 31, 2025 | ||||
| SAFE | Mar 22, 2023 | ||||
| Series A Extension | Feb 22, 2023 | ||||
| Series A | Apr 22, 2022 | ||||
Debt | Nov 24, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Invea Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Series A, Series A Extension |
| ThinkEquity | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
Monthly visitors grew 1200% MoM, from 1.2K to 16K.
- Mar 6, 2026
Raised $35M at a $127.5M valuation.
For institutional investors. Book with your work email.
Invea Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Invea Therapeutics's valuation, stock price, and market status.
Is Invea Therapeutics a public or private company?
Invea Therapeutics is a private company.
What is the current stock price of Invea Therapeutics?
Invea Therapeutics is a private company, so its shares have no public market price. Caplight tracks Invea Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Invea Therapeutics worth (valuation)?
Invea Therapeutics's valuation is estimated at $127.5M based on funding round data.
Can I buy Invea Therapeutics stock?
Invea Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Invea Therapeutics's last funding round?
Invea Therapeutics's most recent funding round was IPO on March 6, 2026.
Who are the main investors in Invea Therapeutics?
Key investors in Invea Therapeutics include ThinkEquity.
Will Invea Therapeutics IPO soon?
No public IPO plans have been announced for Invea Therapeutics.
How can I track Invea Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Invea Therapeutics's shares on secondary markets.